New treatment options for vitiligo
Novel Small Molecule Therapeutic for Vitiligo
This study is looking at a new treatment for vitiligo, a condition that causes skin to lose its color, by targeting a specific protein that plays a role in the disease, with the goal of finding effective and affordable options to help improve the lives of people with vitiligo.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Aohbio Corporation NIH-funded |
| Lab location | 1 site (Athens, United States) |
| Project ID | NIH-11005527 on NIH RePORTER |
What this research studies
This research focuses on developing a novel small molecule therapeutic aimed at treating vitiligo, a condition that causes patchy loss of skin pigmentation. The approach involves investigating the autoimmune mechanisms behind vitiligo, particularly the role of the cytokine CXCL10, which is found at high levels in affected skin. By inhibiting the signaling pathways that lead to CXCL10 expression, the researchers aim to create effective and affordable treatments that can improve the quality of life for patients with vitiligo. The research will utilize both murine models and human tissue to test the efficacy of these new compounds.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with vitiligo who are seeking new treatment options.
Not a fit: Patients who do not have vitiligo or those who have already found effective treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective, and cost-efficient treatment option for individuals suffering from vitiligo.
How similar studies have performed: While there is limited research on small molecule therapeutics for vitiligo, the approach of targeting CXCL10 has shown promise in preliminary studies.
Where this research is happening
Athens, United States
- Aohbio Corporation — Athens, United States (Active)
Researchers
- Principal investigator: Mccall, Kelly — Aohbio Corporation
- Study coordinator: Mccall, Kelly
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.